Esserman L - Search Results

1

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Campbell MJ, et al. Among authors: esserman l. J Immunol. 1990 Aug 1;145(3):1029-36. J Immunol. 1990. PMID: 2373859

2

An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.

Takahashi S, Esserman L, Levy R. Takahashi S, et al. Among authors: esserman l. Blood. 1991 Feb 15;77(4):826-32. Blood. 1991. PMID: 1704266 Free article.

3

Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones.

Umetsu DT, Esserman L, Donlon TA, DeKruyff RH, Levy R. Umetsu DT, et al. Among authors: esserman l. J Immunol. 1990 Apr 1;144(7):2550-7. J Immunol. 1990. PMID: 1969451

4

Follicular lymphoma: a model of lymphoid tumor progression in man.

Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S, et al. Zelenetz AD, et al. Among authors: esserman l. Ann Oncol. 1991 Feb;2 Suppl 2:115-22. doi: 10.1007/978-1-4899-7305-4_18. Ann Oncol. 1991. PMID: 2049308 Free article. Review.

5

An epitope of the transferrin receptor is exposed on the cell surface of high-grade but not low-grade human lymphomas.

Esserman L, Takahashi S, Rojas V, Warnke R, Levy R. Esserman L, et al. Blood. 1989 Dec;74(8):2718-29. Blood. 1989. PMID: 2479430 Free article.

6

Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.

Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Campbell MJ, et al. Among authors: esserman l. Int Rev Immunol. 1989;4(4):251-70. doi: 10.3109/08830188909044782. Int Rev Immunol. 1989. PMID: 2519929 Review. No abstract available.

7

Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.

Campbell MJ, Esserman L, Levy R. Campbell MJ, et al. Among authors: esserman l. J Immunol. 1988 Nov 1;141(9):3227-33. J Immunol. 1988. PMID: 3049819

8

Biological therapies for breast carcinoma: concepts for improvement in survival.

Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM. Borden EC, et al. Among authors: esserman l. Semin Oncol. 1999 Aug;26(4 Suppl 12):28-40. Semin Oncol. 1999. PMID: 10482192 Review.

9

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.

Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM; I-SPY2 Investigators; Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Campbell MJ, et al. Among authors: esserman l. Cell Rep Med. 2024 Nov 19;5(11):101799. doi: 10.1016/j.xcrm.2024.101799. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510069 Free PMC article.

10

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.

Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Among authors: esserman lj. Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39625569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

490 results

Search Page

Filters